Literature DB >> 22587639

Does a screening questionnaire for familial and hereditary colorectal cancer risk work in a health insurance population?

C Pieper1, I Kolankowska, K-H Jöckel.   

Abstract

The aim of our study was to evaluate actual prevalence, uptake and first experiences with a questionnaire developed for early detection of colorectal cancer (CRC) in persons with familial/hereditary risk. A cross sectional study in an insurance population aged 30-54 years was conducted. Subjects with ICD-10 codes C00 to C97 and D37 to D48 were excluded. A standardised questionnaire was sent to 12,139 subjects. Three months later, subjects with a reported family history were followed by a second questionnaire. An additional telephone survey was performed to validate responses. Nineteen per cent met the inclusion criteria (mean age 45 ± 7 years, 38% men). Three hundred and seventy-three subjects (16%) were followed by a second questionnaire. Of these, 248 (66%) returned. Forty-four per cent were already aware of their increased risk of developing CRC. Awareness was associated with knowledge of CRC. One hundred subjects (41%) reported that they had informed their general practitioner (GP) or gastroenterologist. A colonoscopy or stool test was recommended to 92. Subjects who found out about their increased risk for the first time, reported significantly less frequent physician contact (GP: 20% vs. 34%, gastroenterologist: 8% vs. 21%). Results indicate that there is a need for a structured, person at risk-adapted, statutory early detection program.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2012        PMID: 22587639     DOI: 10.1111/j.1365-2354.2012.01358.x

Source DB:  PubMed          Journal:  Eur J Cancer Care (Engl)        ISSN: 0961-5423            Impact factor:   2.520


  7 in total

Review 1.  What characterizes cancer family history collection tools? A critical literature review.

Authors:  J E Cleophat; H Nabi; S Pelletier; K Bouchard; M Dorval
Journal:  Curr Oncol       Date:  2018-08-14       Impact factor: 3.677

2.  Feasibility of Utilizing PREMM Score for Lynch Syndrome Identification in an Urban, Minority Patient Population.

Authors:  Brigid Adviento; Michael Conner; Alexander Sarkisian; Nicolette Walano; Hans Andersson; Jordan Karlitz
Journal:  J Prim Care Community Health       Date:  2021 Jan-Dec

3.  Validation of an online questionnaire for identifying people at risk of familial and hereditary colorectal cancer.

Authors:  F G J Kallenberg; J E G IJspeert; P M M Bossuyt; C M Aalfs; E Dekker
Journal:  Fam Cancer       Date:  2015-09       Impact factor: 2.375

4.  Positive family history of colorectal cancer in a general practice setting [FRIDA.Frankfurt]: study protocol of a of a cross-sectional study.

Authors:  Andrea Siebenhofer; Jasper Plath; Maja Taubenroth; Susanne Singer; Marlene Hechtner; Anne Dahlhaus; Sandra Rauck; Sylvia Schulz-Rothe; Insa Koné; Ferdinand M Gerlach
Journal:  BMC Cancer       Date:  2015-08-28       Impact factor: 4.430

Review 5.  Family history tools for primary care: A systematic review.

Authors:  Špela Miroševič; Zalika Klemenc-Ketiš; Borut Peterlin
Journal:  Eur J Gen Pract       Date:  2022-12       Impact factor: 3.636

6.  Identification of hereditary cancer in the general population: development and validation of a screening questionnaire for obtaining the family history of cancer.

Authors:  Natalia Campacci; Juliana O de Lima; André L Carvalho; Rodrigo D Michelli; Rafael Haikel; Edmundo Mauad; Danilo V Viana; Matias E Melendez; Fabiana de L Vazquez; Cleyton Zanardo; Rui M Reis; Benedito M Rossi; Edenir I Palmero
Journal:  Cancer Med       Date:  2017-10-21       Impact factor: 4.452

7.  Evaluating the effects of a risk-adapted screening program for familial colorectal cancer in individuals between 25 and 50 years of age: study protocol for the prospective population-based intervention study FARKOR.

Authors:  Sabine Hoffmann; Alexander Crispin; Doris Lindoerfer; Gaby Sroczynski; Uwe Siebert; Ulrich Mansmann; Farkor Consortium
Journal:  BMC Gastroenterol       Date:  2020-05-05       Impact factor: 3.067

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.